An inhibitor of Bcl-2 family proteins induces regression of solid tumours

@article{Oltersdorf2005AnIO,
  title={An inhibitor of Bcl-2 family proteins induces regression of solid tumours},
  author={T. Oltersdorf and S. W. Elmore and Alexander R. Shoemaker and R. C. Armstrong and D. J. Augeri and B. A. Belli and M. Bruncko and T. Deckwerth and J. Dinges and P. Hajduk and M. K. Joseph and Shin-ichi Kitada and S. Korsmeyer and A. Kunzer and A. Letai and Chi Li and M. Mitten and D. Nettesheim and Shichung Ng and P. Nimmer and J. O'Connor and A. Oleksijew and A. Petros and John Calvin Reed and W. Shen and Stephen K. Tahir and C. Thompson and K. Tomaselli and B. Wang and M. D. Wendt and H. Zhang and S. Fesik and S. Rosenberg},
  journal={Nature},
  year={2005},
  volume={435},
  pages={677-681}
}
  • T. Oltersdorf, S. W. Elmore, +30 authors S. Rosenberg
  • Published 2005
  • Chemistry, Medicine
  • Nature
  • Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-XL and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-XL expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Phase I/II, Multicenter, Open Label, Clinical Trial to evaluate safety and efficacy and determine the Maximum Tolerated Dose (MTD) of Filanesib in combination with pomalidomide and… Expand
    ConditionsMultiple Myeloma
    InterventionDrug
    Non‐peptidic small molecule inhibitors against Bcl‐2 for cancer therapy
    110
    Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
    76
    Inhibitors of the Bcl-2 Protein Family as Sensitizers to Anticancer Agents
    1
    A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    137
    Hematologic malignancies: newer strategies to counter the BCL-2 protein
    17

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 34 REFERENCES
    Promise and problems of Bcl-2 antisense therapy.
    52
    Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
    409